Nitazoxanide Versus Placebo for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
Respiratory viruses are a significant cause of hospitalization for respiratory tract
infections. This study will evaluate the safety, effectiveness, and tolerability of
nitazoxanide (NTZ) in treating severe acute respiratory illness (SARI) in people who are
hospitalized.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Mexican Emerging Infectious Diseases Clinical Research Network